Litt’s Drug profile for Abemaciclib


BreastfeedingPediatric
  • Trade Name: Verzenio (Lilly)
  • Indications: Hormone receptor-positive, human epidermal growth factor 2-negative advanced or metastatic breast cancer, either as monotherapy or in combination with fulvestrant; or as inital endocrine-based therapy with an aromatase inhibitor
  • Class: Cyclin-dependent kinase (CDK) 4/6 inhibitor
  • Half-life: 18 hours
  • FDA Approval Date: 09/28/2017
  • Clinically important, potentially hazardous interactions with:
    Grapefruit Juice, Ketoconazole, Strong CYP3A4 inducers or inhibitors
  • Pregnancy: Can cause fetal harm

Please login to view the rest of this drug profile.

Page last updated 03/23/2026

Symbol key

Incidence - Help

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness - Help

Hospitalization possible
Life threatening
Fatal

Warnings in other populations - Help

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric